Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?
作者： Sean G. Kelly , Amesika N. Nyaku , Babafemi O. Taiwo
DOI: 10.1007/S40265-016-0553-8
关键词:
摘要: The advent of combination antiretroviral therapy (ART) has significantly decreased AIDS-related morbidity and mortality. Nevertheless, the benefits ART are only realized through adherence to lifelong treatment. Though contemporary (ARV) drugs have fewer adverse effects in comparison older ARV drugs, many agents associated with negative or unknown long-term effects. There is increasing evidence that two-drug (dual-therapy) regimens may be an effective alternative currently recommended three-drug (triple-therapy) regimens. In this review, we provide a comprehensive critical review recently completed ongoing trials dual-therapy treatment-naive treatment-experienced HIV-1-infected patients. We also current HIV/AIDS society recommendations regarding dual as well future therapeutic possibilities.
springer.com
sci-hub.se 参考文章(32)
José R Arribas, Pierre-Marie Girard, Roland Landman, Judit Pich, Josep Mallolas, María Martínez-Rebollar, Francisco X Zamora, Vicente Estrada, Manuel Crespo, Daniel Podzamczer, Joaquín Portilla, Fernando Dronda, José A Iribarren, Pere Domingo, Federico Pulido, Marta Montero, Hernando Knobel, André Cabié, Laurence Weiss, José M Gatell, None, Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial Lancet Infectious Diseases. ,vol. 15, pp. 785- 792 ,(2015) , 10.1016/S1473-3099(15)00096-1
José A Perez-Molina, Rafael Rubio, Antonio Rivero, Juan Pasquau, Ignacio Suárez-Lozano, Melcior Riera, Miriam Estébanez, Jesús Santos, José Sanz-Moreno, Jesús Troya, Ana Mariño, Antonio Antela, Jordi Navarro, Herminia Esteban, Santiago Moreno, None, Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial Lancet Infectious Diseases. ,vol. 15, pp. 775- 784 ,(2015) , 10.1016/S1473-3099(15)00097-3
David A Margolis, Cynthia C Brinson, Graham H R Smith, Jerome de Vente, Debbie P Hagins, Joseph J Eron, Sandy K Griffith, Marty H St Clair, Marita C Stevens, Peter E Williams, Susan L Ford, Britt S Stancil, Melinda M Bomar, Krischan J Hudson, Kimberly Y Smith, William R Spreen, Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial Lancet Infectious Diseases. ,vol. 15, pp. 1145- 1155 ,(2015) , 10.1016/S1473-3099(15)00152-8
Jeanne M. Marrazzo, Carlos del Rio, David R. Holtgrave, Myron S. Cohen, Seth C. Kalichman, Kenneth H. Mayer, Julio S. G. Montaner, Darrell P. Wheeler, Robert M. Grant, Beatriz Grinsztejn, N. Kumarasamy, Steven Shoptaw, Rochelle P. Walensky, Francois Dabis, Jeremy Sugarman, Constance A. Benson, HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. ,vol. 312, pp. 390- 409 ,(2014) , 10.1001/JAMA.2014.7999
Jacques Reynes, Roger Trinh, Federico Pulido, Ruth Soto-Malave, Joseph Gathe, Roula Qaqish, Min Tian, Linda Fredrick, Thomas Podsadecki, Michael Norton, Angela Nilius, Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Research and Human Retroviruses. ,vol. 29, pp. 256- 265 ,(2012) , 10.1089/AID.2011.0275
C. Katlama, L. Assoumou, M.-A. Valantin, C. Soulie, C. Duvivier, L. Chablais, S. Kolta, G. Pialoux, P. Mercie, A. Simon, D. Costagliola, G. Peytavin, A.-G. Marcelin, C. Katlama, A. Simon, M. A. Valantin, L. Assoumou, D. Costagliola, C. Soulie, V. Calvez, A. G. Marcelin, G. Peytavin, C. Katlama, A. Simon, M. A. Valantin, L. Assoumou, D. Costagliola, L. Chablais, G. Peytavin, J. Capeau, J.- P. Bastard, S. Kolta, C. Soulie, V. Calvez, A. G. Marcelin, S. Couffin Cadiergues, J. Saillard, X. Rey-Coquais, F. Durand, C. Lemarchand, L. Cuzin, J. P. Aboulker, H. Fisher, , Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study Journal of Antimicrobial Chemotherapy. ,vol. 69, pp. 1648- 1652 ,(2014) , 10.1093/JAC/DKT536
Babafemi Taiwo, Lu Zheng, Sebastien Gallien, Roy M Matining, Daniel R Kuritzkes, Cara C Wilson, Baiba I Berzins, Edward P Acosta, Barbara Bastow, Peter S Kim, Joseph J Eron Jr, ACTG A5262 Team, Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. ,vol. 25, pp. 2113- 2122 ,(2011) , 10.1097/QAD.0B013E32834BBAA9
Roger J. Bedimo, Henning Drechsler, Mamta Jain, James Cutrell, Song Zhang, Xilong Li, Irfan Farukhi, Rosinda Castanon, Pablo Tebas, Naim M. Maalouf, The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health PLoS ONE. ,vol. 9, pp. e106221- ,(2014) , 10.1371/JOURNAL.PONE.0106221
Michael J. Kozal, Sergio Lupo, Edwin DeJesus, Jean-Michel Molina, Cheryl McDonald, Francois Raffi, Jorge Benetucci, Marco Mancini, Rong Yang, Victoria Wirtz, Lisa Percival, Jenny Zhang, Li Zhu, Dilek Arikan, Awny Farajallah, Bach-Yen Nguyen, Randi Leavitt, Donnie McGrath, Max Lataillade, , A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. Hiv Clinical Trials. ,vol. 13, pp. 119- 130 ,(2012) , 10.1310/HCT1303-119
Mauro Zaccarelli, Massimiliano Fabbiani, Carmela Pinnetti, Vanni Borghi, Alberto Giannetti, Gaetana Sterrantino, Patrizia Lorenzini, Alessandra Latini, Laura Loiacono, Manuela Colafigli, Adriana Ammassari, Gabriella D'Ettorre, Maddalena Plazzi, Simona Di Giambenedetto, Andrea Antinori, Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis Journal of the International AIDS Society. ,vol. 17, pp. 19802- 19802 ,(2014) , 10.7448/IAS.17.4.19802